On Friday, Shares of AstraZeneca plc (ADR) (NYSE:AZN), lost -0.28% to $32.36.
Cardiovascular disease is a leading cause of death, globally. In the United States, every 33 seconds someone dies of heart disease, making it the number one cause of death among American adults. This is why one day each year, September 29, is devoted to raising awareness about cardiovascular disease: World Heart Day. This World Heart Day, together, the National Forum for Heart Disease & Stroke Prevention and AstraZeneca will bring attention to the importance of cholesterol administration and cardiovascular disease.
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide.
Shares of Keryx Biopharmaceuticals (NASDAQ:KERX), declined -8.79% to $3.63, during its last trading session.
Keryx Biopharmaceuticals, declared that the European Commission has approved Fexeric(R) (ferric citrate coordination complex) for the control of elevated serum phosphorus levels, or hyperphosphatemia, in adults with chronic kidney disease (CKD), counting both dialysis and pre-dialysis patients. The European Commission considered ferric citrate coordination complex a New Active Substance, which provides 10 years of data and marketing exclusivity in Europe.
“We are happy that this medicine was approved for broad use, in both the pre-dialysis and dialysis settings, to control hyperphosphatemia in adults with chronic kidney disease,” said John Neylan, M.D., chief medical officer of Keryx. “Importantly, the EU product information contains data that is reflective of Fexeric’s full clinical profile, counting all of the primary and secondary endpoint data from the Phase 3 study. With Fexeric’s broad label, nephrologists have a new, well tolerated and effective phosphate binder to control hyperphosphatemia as the patient progresses through the late stages of CKD and into dialysis.”
The European Commission’s decision is based on evidence from about 1900 patients, counting two key clinical trials: a Phase 2, non-dialysis study and a 58-week, Phase 3 registration trial. In the Phase 3 trial, ferric citrate effectively reduced serum phosphorus levels to within the KDOQI guidelines range of 3.5 mg/dL to 5.5 mg/dL (p<0.0001), the primary endpoint. These data were published in 2014 in the Journal of the American Society of Nephrology.
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, in addition to treats iron deficiency anemia. Auryxia is also used to control serum phosphorus levels in patients with chronic kidney disease on dialysis.
Finally, Electronic Arts Inc. (NASDAQ:EA), ended its last trade with 0.99% gain, and closed at $69.49.
Electronic Arts Inc., declared that EA SPORTS™ FIFA 16, winner of the E3 2015 Game Critics Best Sports Game award, is now available in retail stores and as a digital download* worldwide. FIFA 16 has been described by Digital Spy (UK) as, “an impressive beast of a game that’s stuffed with official leagues and licenses, game modes and other little touches that add flavor to the match day experience,” and hailed by EGM (USA) as, “an unparalleled soccer simulation that improves upon FIFA 15 in every aspect.” With gameplay innovation across the entire pitch and brand new ways to play, FIFA 16 lets fans Play Beautiful.
“It has been incredible to see the number of fans already engaging in and enjoying FIFA 16 through EA Access and our preseason demo,” said Nick Channon, Senior Producer of EA SPORTS FIFA. “We are very excited with the early feedback, particularly on the balanced gameplay, and now that the game is launching across the globe, we shift our focus to providing the best live service in the industry.”
Electronic Arts Inc. develops, markets, publishes, and distributes game software content and online services for video game consoles, Internet-connected consoles, personal computers, mobile phones, and tablets worldwide. The company operates through EA Studios, EA Mobile, and Maxis divisions.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
